Mesoblast Ltd (MESO)

NASDAQ

$16.63

Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.

Sector:

Industry:

68 analysts

Strong Buy

Target: $35 (+110.46%)

Market Cap

$2.36B

Revenue 5Y CAGR

+32.03%

Free Cash Flow Yield

-2.22%

Beta (5Y)

1.39

Adjust inflation

Log

Valuation

Market Cap$2.36B

Forward P/E454.55

P/S33.10

P/B3.77

Profitability

Total Revenue (TTM)$65M

Gross Profit (TTM)-$23M

EBITDA-$64M

Profit Margin-78.2%

Operating Margin-55.2%

EPS-$0.74

Financial Health

Debt-to-Equity23.5%

Free Cash Flow Yield-2.22%

Growth & Risk

EPS 5Y CAGR-15.82%

Revenue 5Y CAGR+32.03%

FCF 5Y CAGR+2.09%

Beta (5Y)1.39

Sharpe Ratio0.72